Clinical Data gets app nod for depression drug

May 24, 2010

(AP) -- Federal regulators have accepted an application for a depression drug marketed by Clinical Data Inc., the company said Monday.

The acceptance of vilazodone, officially made Friday by the , triggered a $15.6 million payment by Clinical Data to Merck Serono, which developed the drug.

In June 2009, Clinical Data said vilazodone met its goals in a late-stage clinical trial as a treatment for major .

Merck Serono is a unit of German drug maker Merck KGaA, and is not connected to New Jersey-based Merck and Co.

Explore further: Merck's Vioxx cases drag on

0 shares

Related Stories

Merck's Vioxx cases drag on

August 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Trials find no benefits of Zetia

January 15, 2008

The U.S. makers of the cholesterol-lowering drug Zetia say a clinical trial failed to identify any medical benefits of the medication.

FDA to review Vytorin results

January 26, 2008

The U.S. Food and Drug Administration said it is conducting a review of the cholesterol drug Vytorin based on preliminary results from a recent study.

FDA considers expanded use of HPV vaccine

March 20, 2008

Pharmaceutical manufacturer Merck & Co. Inc. said the U.S. Food and Drug Administration will consider expanding the use of its cervical cancer vaccine.

FDA won't accept Merck's application for new drug

November 2, 2009

(AP) -- U.S. regulators have refused to accept drugmaker Merck & Co.'s application for a new, combination cholesterol pill that includes rival Pfizer's Lipitor, the world's top-selling drug.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.